B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.

ABSTRACT:

Background and purpose

Recent findings document a blunted humoral response to SARS-CoV-2 vaccination in patients on anti-CD20 treatment. Although most patients develop a cellular response, it is still important to identify predictors of seroconversion to optimize vaccine responses.

Methods

We determined antibody responses after SARS-CoV-2 vaccination in a real-world cohort of multiple sclerosis patients (n = 94) treated with anti-CD20, mainly rituximab, with variable treatment duration (median = 2.9, range = 0.4-9.6 years) and time from last anti-CD20 infusion to vaccination (median = 190, range = 60-1032 days).

Results

We find that presence of B cells and/or rituximab in blood predict seroconversion better than time since last infusion. Using multiple logistic regres

SUBMITTER: Asplund Hogelin K 

PROVIDER: S-EPMC9349816 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature